At One Month Post Launch, the Majority of Surveyed Urologists and Oncologists Expect to Prescribe Astellas Pharma/Medivation’s

  At One Month Post Launch, the Majority of Surveyed Urologists and
  Oncologists Expect to Prescribe Astellas Pharma/Medivation’s Xtandi Within
  the Next Six Months or Sooner; Xtandi is Viewed as a Major Threat to
  Janssen’s Zytiga

 On Average, Surveyed Oncologists are Significantly More Willing to Prescribe
 Xtandi Compared with Surveyed Urologists; Nevertheless, the Majority of Both
         Specialist Types Report High Willingness to Prescribe Xtandi

Business Wire

EXTON, Pa. -- November 29, 2012

BioTrends Research Group, one of the world’s leading research and advisory
firms for specialized biopharmaceutical issues, finds that at one month
following launch, less than 10 percent of surveyed urologists, but more than a
third of oncologists say they have used Astellas Pharma/Medivation’s Xtandi
(enzalutamide) in clinical practice for the treatment of prostate cancer.
According to the data published in the first wave of the LaunchTrends^® Xtandi
report series, the lack of familiarity with Xtandi is the greatest factor
currently holding urologists back from prescribing Xtandi. Of current
non-prescribers, the majority of oncologists say that they will prescribe
Xtandi within the next three months or sooner; although urologists say that
they will take longer before they prescribe Xtandi, the majority say they will
prescribe it in the next six months or sooner.

“The launch of Xtandi is a major threat to Zytiga’s continued growth in
post-docetaxel metastatic castrate-resistant prostate cancer (MCRPC),” said
Oncology Therapeutic Class Director, Andrew Merron, Ph.D. “Urologists and
oncologists frequently cite Zytiga and Sanofi’s Jevtana as being the currently
available therapies which Xtandi is most likely to displace. Approximately one
half of surveyed physicians have a more favorable opinion of Xtandi versus
Zytiga, compared to less than 15 percent who have a more favorable opinion of
Zytiga versus Xtandi. Nevertheless, a large proportion of respondents consider
these agents equivalent.”

With respect to safety, a greater proportion of surveyed physicians believe
that Xtandi has a better toxicity profile than Zytiga versus those who think
Xtandi has a poorer toxicity profile than Zytiga (although generally
physicians think that Xtandi and Zytiga have comparable overall toxicities).
Seizure is the safety issue which is most commonly perceived to be a greater
concern with Xtandi compared with other agents used to treat
docetaxel-pretreated MCRPC.

Both Zytiga and Xtandi have potential to penetrate earlier disease settings;
should both products gain approval in asymptomatic/minimally symptomatic
MCRPC, most respondents say that they will prescribe Xtandi in place of
Zytiga.

LaunchTrends: Xtandi  is a series of three post-launch syndicated reports
designed to track physician perception, uptake and the competitive environment
of Xtandi in MCRPC. For this first wave of research, which measures Xtandi’s
market impact at one month following launch, BioTrends surveyed oncologists
(n=49) and urologists (n=49) in the United States and conducted qualitative
interviews with 15 physicians in October 2012. BioTrends evaluates the threat
of current and emerging therapies on Xtandi. BioTrends will continue to track
Xtandi in subsequent waves of research.

About BioTrends Research Group

BioTrends Research Group provides syndicated and custom primary market
research to pharmaceutical manufacturers competing in clinically evolving,
specialty pharmaceutical markets. For information on BioTrends publications
and research capabilities, please contact us at (610) 321-9400 or
www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
www.DecisionResourcesGroup.com.

    All company, brand, or product names contained in this document may be
                   trademarks of their respective holders.

Contact:

BioTrends Research Group
Dr. Andrew Merron, +44-20-7332-7454
amerron@bio-trends.com
or
Decision Resources Group
Christopher Comfort, 781-993-2597
ccomfort@dresources.com
 
Press spacebar to pause and continue. Press esc to stop.